ADMA Biologics Granted U.S. Patent for Treatment and Prevention of Pneumococcal Infections Apr 17, 2019
ADMA Biologics Submits Response and Provides Supplemental Information to FDA for BIVIGAM® Complete Response Letter Jan 7, 2019
ADMA to Host Conference Call to Discuss Recent Regulatory Update on BIVIGAM® PAS Submissions Dec 20, 2018
